The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | daNIS-3: NIS793 plus anti-PD-1 with SOC in second-line MSS CRC
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses efficacy and safety results from the Phase II daNIS-3 trial (NCT04952753) of NIS793, an anti-TGFβ monoclonal antibody, with tislelizumab and standard of care (SOC) as second-line treatment in patients with microsatellite stable (MSS) colorectal cancer (CRC). The study was terminated early due to an unfavorable benefit-risk profile, with NIS793-containing arms demonstrating a detrimental progression-free survival outcome compared with standard of care. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
